$PULM
Pulmatrix, Inc. Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031478 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$366.0K	$1.552M	$1.844M
YoY Change	-79.12%	-15.84%	38.54%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.209M	$2.001M	$1.670M
YoY Change	27.69%	19.82%	7.53%
% of Gross Profit
Research & Development	$814.0K	$2.834M	$4.165M
YoY Change	-79.46%	-31.96%	-3.97%
% of Gross Profit
Depreciation & Amortization	$0.00	$47.00K	$32.00K
YoY Change	-100.0%	46.88%	-31.91%
% of Gross Profit
Operating Expenses	$3.023M	$7.453M	$5.835M
YoY Change	-46.89%	27.73%	-0.93%
Operating Profit	-$2.657M	-$5.901M	-$3.991M
YoY Change	-32.55%	47.86%	-12.46%
Interest Expense	$101.0K	$133.0K	$236.0K
YoY Change	-54.09%	-43.64%	1473.33%
% of Operating Profit
Other Income/Expense, Net	$70.00K	$90.00K	$175.0K
YoY Change	-57.58%	-48.57%	-443.14%
Pretax Income	-$2.587M	-$5.811M	-$3.816M
YoY Change	-31.38%	52.28%	-16.95%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.587M	-$5.811M	-$3.816M
YoY Change	-31.45%	52.28%	-16.95%
Net Earnings / Revenue	-706.83%	-374.42%	-206.94%
Basic Earnings Per Share	-$0.71	-$1.59	-$1.04
Diluted Earnings Per Share	-$0.71	-$1.59	-$1.04
COMMON SHARES
Basic Shares Outstanding	3.652M shares	3.652M shares	3.652M shares
Diluted Shares Outstanding	3.652M shares	3.652M shares	3.652B shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.78M	$12.38M	$25.79M
YoY Change	-49.48%	-52.0%	-39.89%
Cash & Equivalents	$10.78M	$12.38M	$25.79M
Short-Term Investments
Other Short-Term Assets	$641.0K	$2.622M	$1.172M
YoY Change	-38.95%	123.72%	-48.93%
Inventory
Prepaid Expenses
Receivables	$23.00K	$635.0K	$418.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.45M	$15.64M	$27.38M
YoY Change	-50.73%	-42.89%	-40.27%
LONG-TERM ASSETS
Property, Plant & Equipment			$279.0K
YoY Change			-83.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$54.00K	$93.00K	$1.984M
YoY Change	-75.12%	-95.31%	7.83%
Total Long-Term Assets	$64.00K	$144.0K	$4.012M
YoY Change	-99.53%	-96.41%	12.92%
TOTAL ASSETS
Total Short-Term Assets	$11.45M	$15.64M	$27.38M
Total Long-Term Assets	$64.00K	$144.0K	$4.012M
Total Assets	$11.51M	$15.78M	$31.39M
YoY Change	-68.7%	-49.73%	-36.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$373.0K	$393.0K	$929.0K
YoY Change	-47.24%	-57.7%	27.61%
Accrued Expenses	$161.0K	$1.764M	$1.465M
YoY Change	-93.61%	20.41%	-55.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$590.0K	$2.470M	$3.597M
YoY Change	-86.68%	-31.33%	-35.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$4.347M
YoY Change	-100.0%	-100.0%	-18.87%
Total Long-Term Liabilities	$0.00	$0.00	$4.347M
YoY Change	-100.0%	-100.0%	-18.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$590.0K	$2.470M	$3.597M
Total Long-Term Liabilities	$0.00	$0.00	$4.347M
Total Liabilities	$590.0K	$2.470M	$7.944M
YoY Change	-96.51%	-68.91%	-27.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$295.2M	-$292.6M	-$281.7M
YoY Change	3.38%	3.85%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.92M	$13.31M	$23.45M
YoY Change
Total Liabilities & Shareholders Equity	$11.51M	$15.78M	$31.39M
YoY Change	-68.7%	-49.73%	-36.45%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.587M	-$5.811M	-$3.816M
YoY Change	-31.45%	52.28%	-16.95%
Depreciation, Depletion And Amortization	$0.00	$47.00K	$32.00K
YoY Change	-100.0%	46.88%	-31.91%
Cash From Operating Activities	-$3.059M	-$3.677M	-$4.904M
YoY Change	-26.11%	-25.02%	7.5%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$244.0K	$58.00K
YoY Change	-100.0%	320.69%	-186.57%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$244.0K	-$58.00K
YoY Change	-100.0%	320.69%	-13.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-3.059M	-3.677M	-4.904M
Cash From Investing Activities	0.000	-244.0K	-58.00K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-3.059M	-3.921M	-4.962M
YoY Change	-31.26%	-20.98%	7.19%
FREE CASH FLOW
Cash From Operating Activities	-$3.059M	-$3.677M	-$4.904M
Capital Expenditures	$0.00	$244.0K	$58.00K
Free Cash Flow	-$3.059M	-$3.921M	-$4.962M
YoY Change	-31.26%	-20.98%	10.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3652285	shares
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4165000	usd
	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	825000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5811000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2024Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent		usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q2	PULM	Loss On Disposal Group Held For Sale LossOnDisposalGroupHeldForSale		usd
	PULM	Loss On Disposal Group Held For Sale LossOnDisposalGroupHeldForSale		usd
	PULM	Loss On Disposal Group Held For Sale LossOnDisposalGroupHeldForSale		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	PULM	Reduction Of Operating Lease Rightofuse Asset And Lease Liability Upon Lease Modification ReductionOfOperatingLeaseRightofuseAssetAndLeaseLiabilityUponLeaseModification		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross		usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2024Q2	PULM	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment		usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent		pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount		usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36199
	dei	Entity Registrant Name EntityRegistrantName	PULMATRIX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1821392
	dei	Entity Address Address Line1 EntityAddressAddressLine1	945 Concord Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1217
	dei	Entity Address City Or Town EntityAddressCityOrTown	Framingham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01701
	dei	City Area Code CityAreaCode	(888)
	dei	Local Phone Number LocalPhoneNumber	355-4440
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	PULM
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3652285	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12379000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19173000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1421000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	635000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	928000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1201000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	742000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	15636000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	20843000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1158000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10309000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	51000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	93000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	176000	usd
CY2024Q2	us-gaap	Assets Assets	15780000	usd
CY2023Q4	us-gaap	Assets Assets	33958000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	393000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1915000	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1783000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	947000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	429000	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	270000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	618000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2470000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3909000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3727000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8327000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2470000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	15963000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3652285	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3652285	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3652285	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305893000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305592000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292583000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-287597000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	13310000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	17995000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15780000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33958000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1552000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1844000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7437000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3343000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2834000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6346000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8039000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2001000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1670000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3627000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3880000	usd
CY2024Q2	PULM	Loss On Disposal Group Held For Sale LossOnDisposalGroupHeldForSale	2618000	usd
	PULM	Loss On Disposal Group Held For Sale LossOnDisposalGroupHeldForSale	2618000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	7453000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	5835000	usd
	us-gaap	Operating Expenses OperatingExpenses	12591000	usd
	us-gaap	Operating Expenses OperatingExpenses	11919000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5901000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3991000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5154000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8576000	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	133000	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	236000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	293000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	458000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-61000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-125000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-146000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	90000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	175000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	168000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	312000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5811000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3816000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4986000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8264000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3652285	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3652285	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3652285	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3652285	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3652285	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3652285	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3651531	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3651531	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	17995000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	198000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	19018000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	19018000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	103000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	13310000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	13310000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31109000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	296000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4448000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27010000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27010000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	255000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3816000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3816000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23449000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23449000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4986000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8264000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	106000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	329000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	777000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	301000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	551000	usd
	PULM	Loss On Disposal Group Held For Sale LossOnDisposalGroupHeldForSale	2618000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-293000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-880000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	459000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-49000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-83000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1595000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1522000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-309000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1225000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-437000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-309000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-843000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4075000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-705000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6396000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9832000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	398000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-398000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6794000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9837000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20645000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37253000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13851000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27416000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12379000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25791000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1421000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	153000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	51000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13851000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27416000	usd
	PULM	Reduction Of Operating Lease Rightofuse Asset And Lease Liability Upon Lease Modification ReductionOfOperatingLeaseRightofuseAssetAndLeaseLiabilityUponLeaseModification	8423000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	50000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	344000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zLzYKKyYJB98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zhZcMX1wTAP5">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s condensed consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue and estimates related to clinical trial accruals and upfront deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zzOXXkpSaNwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zuZLD5vdxVec">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy, and the Company has not incurred any losses to date. The Company is exposed to credit risk in the event of default by this financial institution for amounts in excess of the Federal Deposit Insurance Corporation insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2024, revenue from one customer accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_ziQZagZ0KA96" title="Concentration risk percentage">61</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zp1m27hn9Nbh" title="Concentration risk percentage">89</span>%, respectively, of revenue recognized in the accompanying condensed consolidated financial statements. For the three and six months ended June 30, 2023, revenue from one customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zPS6yGRSZlY6" title="Concentration risk percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zoIaHg3uE78b" title="Concentration risk percentage">100</span></span>% of revenue recognized in the accompanying condensed consolidated financial statements. As of June 30, 2024, two customers accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zmdC67TpHkj7" title="Concentration risk percentage">100</span>% of accounts receivable. As of December 31, 2023, one customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zRYlveo9t6Ld" title="Concentration risk percentage">100</span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	PULM	Prepaid Clinical And Consulting PrepaidClinicalAndConsulting	457000	usd
CY2023Q4	PULM	Prepaid Clinical And Consulting PrepaidClinicalAndConsulting	30000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	438000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	232000	usd
CY2024Q2	PULM	Prepaid Software And Hosting Costs PrepaidSoftwareAndHostingCosts	86000	usd
CY2023Q4	PULM	Prepaid Software And Hosting Costs PrepaidSoftwareAndHostingCosts	108000	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	220000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	372000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1201000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	742000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2894000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1736000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1158000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	106000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	64000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1221000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	296000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	347000	usd
CY2023Q4	PULM	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	389000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	43000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	99000	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1783000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	947000	usd
	PULM	Agreement Description AgreementDescription	Pursuant to the Second Amendment, the Company and Cipla were each responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). The Company will share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis.
CY2024Q2	PULM	Transaction Costs TransactionCosts	22000000.0	usd
	PULM	Disoposal Of Carrying Value DisoposalOfCarryingValue	2600000	usd
	PULM	Warrants Issued Or Exercised WarrantsIssuedOrExercised	0	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	160445	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.12
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	255000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	301000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	551000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	271000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	418000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	678000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	796000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	104000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	168000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	206000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	281000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	375000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	586000	usd
	us-gaap	Lease Cost LeaseCost	884000	usd
	us-gaap	Lease Cost LeaseCost	1077000	usd
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	322000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	432000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	657000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	863000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y2M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0840	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	24000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	24000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	24000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1312485	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1554747	shares

Files In Submission

Name	View Source	Status
0001493152-24-031478-index-headers.html	Edgar Link	pending
0001493152-24-031478-index.html	Edgar Link	pending
0001493152-24-031478.txt	Edgar Link	pending
0001493152-24-031478-xbrl.zip	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-4_002.jpg	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pulm-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pulm-20240630_cal.xml	Edgar Link	unprocessable
pulm-20240630_pre.xml	Edgar Link	unprocessable
pulm-20240630_lab.xml	Edgar Link	unprocessable
pulm-20240630_def.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix, Inc. Stock $pulm

2024 Q3 Form 10-Q Financial Statement

#000149315224031478 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix, Inc. Stock $pulm

2024 Q3 Form 10-Q Financial Statement

#000149315224031478 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix, Inc. Stock $pulm